OptimizeRx (OPRX) Cost of Revenue (2013 - 2026)

OptimizeRx (OPRX) has 14 years of Cost of Revenue data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 42.78% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $32.2 million (down 4.98% YoY), and the FY2025 full-year result was $35.8 million, up 9.42% from the prior year.
• Cost of Revenue fell to $4.9 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10.6 million in Q2 2025 to a low of $4.9 million in Q1 2026.
• A 5-year average of $7.4 million and a median of $7.2 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 48.56% in 2025 and plunged 42.78% in 2026, its largest moves.
• Tracing OPRX's Cost of Revenue over 5 years: stood at $7.2 million in 2022, then jumped by 46.22% to $10.5 million in 2023, then dropped by 2.23% to $10.3 million in 2024, then slipped by 20.93% to $8.1 million in 2025, then sank by 39.65% to $4.9 million in 2026.
• Business Quant data shows OPRX's Cost of Revenue at $4.9 million in Q1 2026, $8.1 million in Q4 2025, and $8.6 million in Q3 2025.